Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25489380 | 0.80 | — | — | |
| SCHEMBL25544254 | 0.78 | — | — | |
| SCHEMBL12526115 | 0.78 | SYK (0.33) | SYKKCNH2AURKB | |
| SCHEMBL25912622 | 0.74 | — | — | |
| SCHEMBL21462466 | 0.74 | ARG1 (0.35) | SYKKCNH2AURKB | |
| SCHEMBL21483088 | 0.74 | ARG1 (0.35) | SYKKCNH2AURKB | |
| SCHEMBL12527141 | 0.74 | ARG1 (0.35) | SYKKCNH2AURKB | |
| SCHEMBL28411820 | 0.73 | SYK (0.38) | SYKKCNH2AURKB | |
| SCHEMBL18968854 | 0.73 | SYK (0.30) | SYKKCNH2AURKB | |
| SCHEMBL24768332 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-10633361-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2020-04-28 | — | — | US | disclosed |
| US-20170204079-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2017-07-20 | — | — | US | disclosed |
| US-9598355-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2017-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | SYK 4399/4885KCNH2 1966/4885AURKB 2505/4885 |
| US-20170204079-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | SYK 4549/4885KCNH2 4140/4885AURKB 3806/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | SYK 4399/4885KCNH2 1966/4885AURKB 2505/4885 |
| US-10633361-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, CRYZ, TCF12 | SYK 4549/4885KCNH2 4140/4885AURKB 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.